← Browse by Condition
Medical Condition

duchenne muscular dystrophy

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for duchenne muscular dystrophy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — duchenne muscular dystrophy Clinical Trials

How many clinical trials are currently recruiting for duchenne muscular dystrophy?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for duchenne muscular dystrophy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for duchenne muscular dystrophy?
duchenne muscular dystrophy research spans Phase 1 (1 trial), Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a duchenne muscular dystrophy clinical trial?
Eligibility criteria for duchenne muscular dystrophy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Phase 3
1
Top Sponsors
Masonic Cancer Center, University of Minnesota 1 trial
REGENXBIO Inc. 1 trial
Centre Hospitalier Universitaire de Liege 1 trial

Recruiting Clinical Trials

NCT06692426 Phase 1
Recruiting
Trial of Cell Based Therapy for DMD
Enrollment
8 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
View Trial →
NCT05693142 Phase 2, Phase 3
Recruiting
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
Enrollment
65 pts
Location
United States, Canad...
Sponsor
REGENXBIO Inc.
View Trial →
NCT05982119
Recruiting
Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
Enrollment
300 pts
Location
Belgium, Czechia, Eg...
Sponsor
Centre Hospitalier Universitai...
View Trial →

Related Conditions

fascioscapulohumeral muscular dystrophy (1) myotonic dystrophy 1 (1) charcot marie tooth (1) centronuclear myopathy (1) congenital muscular dystrophy (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology